Danirixin

Cat. No.: HY-19768

CAS No.: 954126-98-8

Molecular Formula: $C_{19}H_{21}ClFN_3O_4S$

Molecular Weight: 441.9

Target: CXCR

Pathway: GPCR/G Protein; Immunology/Inflammation

Storage:

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	2 years
	-20°C	1 year



SOLVENT & SOLUBILITY

In Vitro

DMSO : 8 mg/mL (18.10 mM; Need ultrasonic and warming)

Preparing Stock Solutions

Solvent / Mass / Concentration	1 mg	5 mg	10 mg
1 mM	2.2630 mL	11.3148 mL	22.6296 mL
5 mM	0.4526 mL	2.2630 mL	4.5259 mL
10 mM	0.2263 mL	1.1315 mL	2.2630 mL

Please refer to the solubility information to select the appropriate solvent.

BIOLOGICAL ACTIVITY

Description

Danirixin is a selective, and reversible CXCR2 antagonist, with IC_{50} of 12.5 nM for CXCL8.

IC_{50} & Target

CXCL8-CXCR2
12.5 nM (IC_{50})

In Vitro

Danirixin is a small molecule, CXCR2 antagonist being evaluated as a potential anti-inflammatory medicine[1].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

CUSTOMER VALIDATION

- Cell Death Dis. 2019 Mar 20;10(4):273.
- Front Immunol. 2021 May 7;12:667177.

- Cancer Cell Int. 2021 Jul 3;21(1):337.
- Int J Mol Sci. 2023 Nov 27, 24(23), 16803.
- Int Immunopharmacol. 2021 Mar 5;95:107153.

See more customer validations on www.MedChemExpress.com

REFERENCES

[1]. Miller BE, et al. The pharmacokinetics and pharmacodynamics of danirixin (GSK1325756)--a selective CXCR2 antagonist?--in healthy adult subjects. BMC Pharmacol Toxicol. 2015 Jun 20;16:18.

Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@MedChemExpress.com
Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA